Indication expansion is a common situation we ofter face in the dynamic adjustment of the national medical insurance drug list in China. This study reviewed the experiences of drug price adjustment in typical countries under the condition of indication expansion and summarized the enlightenment to China. Typical countries took variable measures to determine the drug prices after the expansion of new indications such as access after evaluations by indications based on list prices, weighted pricing method based on value and sales, volume-price drug pricing, indication-based pricing based on risk sharing agreements, and drug pricing based on evaluations in the initial access process. Different approaches have different impacts on protecting the financial risk of the medical insurance funds, encouraging research and development and innovation in the pharmaceutical industry, and ensuring the drug accessibility for the insured patients with new indications. We should clarify the main problems and challenges of medical insurance management in the current stage in China, draw on useful experiences, and improve the price adjustment strategies of medical insurance drugs in the case of indication expansion.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |